The Peptides You Bought Online Might Be Dangerous: Dr. Nathan Starke on the Unregulated “Research Chemical” Market

Somewhere in the last few years, peptides went from obscure to inescapable. They’re in podcast ad reads, longevity newsletters, gym locker rooms, and increasingly in vials shipped from websites that label their products “research chemicals, not for human consumption,” a phrase everyone involved understands to be a legal formality.

Dr. Nathan Starke has noticed. “Peptides are all the rage,” he says. “I feel like I don’t go eight to 12 hours without somebody talking about peptides, mentioning them, seeing them somewhere online. I hear even the federal government is talking frequently about peptides.”

As a fellowship-trained urologist and men’s health specialist, Dr. Nathan Starke’s view on peptides is more careful than either camp in this argument would prefer. He’s not a skeptic, and he’s not willing to overstate the evidence either. What worries him most is the supply chain.

The vocabulary, in plain terms

Start with what the word means, because the marketing has made it murkier than it needs to be.

“Peptides are small proteins,” Dr. Starke explains. “The word peptide just means protein, typically shorter chains of amino acids, fundamental building blocks of life, that act as signaling molecules in your body.”

That’s the key idea. Peptides don’t do the work themselves. They tell your body to do it.

Most aren’t foreign substances either. “Typically they’re not foreign substances,” he says, “although some peptides many people have heard of are maybe not found in your body naturally, but are derived from natural compounds that your body already makes. And your body makes thousands of different proteins.”

Peptide therapy, in that framing, is replacement rather than invention. “What peptide therapy does is supplement the ones your body produces less of as you age, or with certain conditions, or even genetics,” Dr. Starke says. “And they are designed to trigger specific biological responses that you’re trying to optimize, things like growth hormone release, tissue healing, improved body composition, improving sexual function, and helping your cognitive clarity.”

That list explains the popularity. It reads like a catalog of everything a person over 40 notices going wrong.

Where the science stands

Here Dr. Starke departs from the wellness-industry script. He volunteers the weakness of the evidence before anyone asks him about it.

“While peptides are a very hot topic right now, to be honest, it’s important to me as a doctor and a scientist to be honest about where the science stands,” Starke says on peptides.

Then he names names. “For some of most of the popular peptides, many of which have goofy scientific names, like BPC-157, CJC-1295, and TB-500, that I’m sure many people have read about in a variety of outlets, we don’t have robust clinical evidence that we would want, to fully establish benefits or characterize the risks of them.”

Read the second half of that sentence carefully, because it’s the part the internet skips. The gap in the data covers both halves of the question: whether these compounds work, and what they do to you. “It’s important to say that out loud,” Dr. Starke says, “that even though I do believe in the potential of these therapies, there’s a lot we don’t know.”

Regulators have reached similar conclusions about those two specific compounds. FDA’s published safety assessments for both BPC-157 and CJC-1295, on its list of bulk drug substances nominated for use in compounding, cite the risk of immunogenicity for certain routes of administration along with “complexities with regard to peptide-related impurities” and characterization of the active ingredient. For BPC-157 the agency notes it “has identified no, or only limited, safety-related information for the proposed routes of administration.” For CJC-1295 it goes further, citing “serious adverse events” including increased heart rate and a systemic vasodilatory reaction, and noting that “available clinical data are limited.” Both nominations were later withdrawn, which changed their regulatory status without changing what the agency said about the data.

Believing in the potential while admitting the uncertainty is an unusual posture. Most public voices on peptides pick one.

Why dismissing patients backfires

The reflexive medical response to an unproven trend is to wave it off. Dr. Starke thinks that reflex is causing measurable harm.

“I’m not the least bit dismissive of peptide therapy,” he says. “I feel like for the general medical establishment to say peptides are bogus, there’s no science behind them, I’m not thinking about it, it’s just short-sighted.”

His reasoning is about consequences rather than open-mindedness. “It sort of does what a lot of patients have come to expect from the medical establishment, which is to ignore their concerns, not listen to them,” he says. “And then they go and do what I would say would be dangerous things.”

That’s the mechanism worth understanding. A patient who reads about a compound, asks his doctor, and gets dismissed doesn’t stop being interested. He stops asking doctors. The curiosity survives and the supervision doesn’t. Then he’s on a forum comparing vendors.

The sourcing is what worries him

Dr. Starke’s central concern is specific.

“What concerns me most is how often people source these compounds anonymously online, from various pharmacies or so-called research chemical production places,” he says, “and take these powerful medicines, often with no medical oversight, and don’t know when to call because something feels off.”

Every clause there is a separate risk.

Anonymously means nobody is accountable for what’s in the vial. So-called research chemical production places means facilities operating outside pharmaceutical manufacturing standards, with no verified purity, no dosing accuracy, no sterility guarantee, and no recourse. This is precisely the impurity and characterization problem FDA flagged. Powerful medicines is a reminder that a compound triggering hormonal cascades is not a vitamin.

And don’t know when to call is the risk people underestimate most. Without a baseline, without labs, without a clinician who knows your history, you have no framework for interpreting a symptom. Is the fatigue the peptide? The dose? Something unrelated that’s now being masked?

Dr. Starke has long urged caution about unregulated products marketed for male performance, and the same logic applies here with the stakes raised. These are injectables engineered to move your endocrine system.

What supervision looks like

His alternative is oversight, not abstinence.

“Patients of Starke Medical will be able to access nearly everything that they’ve read about or have curiosity about,” he says. “But the difference is, it won’t be just them doing it by their lonesome.”

The offer has three components. “What I offer is a structural alternative: proper evaluation, peptide compounds sourced from reputable pharmacies, and regular follow-up with labs and real conversations about how the patient’s actually responding.”

Proper evaluation means establishing what’s wrong before choosing a compound, since some of what people treat with peptides has a better-studied explanation. Reputable sourcing means a licensed pharmacy accountable for what’s in the vial. Follow-up with labs means somebody is watching the numbers over time instead of trusting how you feel.

His summary of the goal is the most quotable line in the conversation: “The goal is to take something that often happens in the shadows, although becoming more mainstream, but still not quite safe, and make it as safe and evidence-informed as possible.”

If you’re already interested

Dr. Starke’s framework suggests a few practical positions.

• Assume the evidence is thinner than the marketing. The compounds with the loudest followings, BPC-157 and CJC-1295, are the two he singles out as lacking the clinical data needed to establish either benefit or risk. FDA’s own assessments say much the same.
• Read “research chemical” as a warning label. The phrase exists to move products outside the rules that protect you. It signals unverified purity, dosing, and sterility.
• Don’t accept a flat dismissal as the final word. If your physician won’t engage, find one who will. The unsupervised path carries more risk than the conversation you couldn’t get.
• Insist on labs and follow-up. Anything that alters signaling in your body needs measurement over time. A one-time purchase isn’t a treatment plan.

Dr. Starke’s peptide therapy position is narrower than a blanket warning. The danger he names is peptides bought anonymously and injected without oversight, and he holds the medical establishment’s habit of refusing the conversation partly responsible for how many people are doing exactly that.